NASDAQ: IGMS - IGM Biosciences, Inc.

Lønnsomhet i seks måneder: -82.45%
Sektor: Healthcare

Kampanjeplan IGM Biosciences, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

IGM Biosciences, Inc., биотехнологическая компания, занимается исследованиями и разработкой антител к иммуноглобулину M (IgM) для лечения рака. Ведущим кандидатом на продукцию компании является IGM-2323, биспецифическое антитело класса IgM, которое проходит фазу 1 клинических испытаний для лечения пациентов с В-клеточной НХЛ и другими В-клеточными злокачественными новообразованиями.

flere detaljer
Он также разрабатывает IGM-8444, антитело класса IgM, нацеленное на белки рецептора смерти 5; и IGM-7354 представляет собой биспецифическое антитело IgM, доставляющее цитокины интерлейкина-15 к клеткам, экспрессирующим PD-L1, для использования при лечении пациентов с солидными и гематологическими злокачественными новообразованиями. IGM Biosciences, Inc. в сотрудничестве с Atreca Inc. и BeiGene Ltd. обнаруживает, разрабатывает и производит новые антитела IgM и IgA, нацеленные на SARS-CoV-2, для потенциального лечения COVID-19; а также сотрудничество в области стратегических исследований и лицензионное соглашение с AbCellera для обнаружения и разработки антител IgM. Ранее компания была известна как Palingen, Inc. и сменила название на IGM Biosciences, Inc. в 2010 году. IGM Biosciences, Inc. была зарегистрирована в 1993 году, ее штаб-квартира находится в Маунтин-Вью, Калифорния.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2019-09-18
ISIN US4495851085
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://igmbio.com
Цена ао 2.09
Prisendring per dag: 0% (2.09)
Prisendring per uke: -67.85% (6.5)
Prisendring per måned: -74.57% (8.22)
Prisendring over 3 måneder: -87.56% (16.8)
Prisendring over seks måneder: -82.45% (11.91)
Prisendring per år: -80.9% (10.94)
Prisendring over 3 år: -87.56% (16.8)
Prisendring over 5 år: -95.39% (45.33)
Prisendring over 10 år: 0% (2.09)
Prisendring siden begynnelsen av året: -67.34% (6.4)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 208.76 1
P/BV 2.19 7
P/E 10.26 9
EV/EBITDA -1.46 0
Total: 4.75

Effektivitet

Navn Betydning Karakter
ROA, % -58.2 0
ROE, % -121.25 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.1587 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 481.97 10
Lønnsomhet Ebitda, % 469.34 10
Lønnsomhet EPS, % 2.85 1
Total: 8.2
Flere detaljer

Transaksjonsdato Avsløringsdato Insider Type Pris Volum Mengde Del opp til, % Del etterpå, % Dokument
14.06.2024 18.06.2024 Decker Lisa Lynn
CHIEF BUSINESS OFFICER		 Salg 7.58 7 406 977 0 0 link
14.06.2024 18.06.2024 Harler Mary Beth
Head, Research & Autoimmunity		 Salg 7.58 11 901 1570 0 -0.01 link
14.06.2024 18.06.2024 Keyt Bruce
CHIEF SCIENTIFIC OFFICER		 Salg 7.58 8 383 1106 0 0 link
14.06.2024 18.06.2024 Schwarzer Fred
CEO AND PRESIDENT		 Salg 7.58 31 563 4164 0 -0.02 link
14.06.2024 18.06.2024 Tahir Misbah
CHIEF FINANCIAL OFFICER		 Salg 7.58 11 901 1570 0 -0.01 link
14.06.2024 18.06.2024 Takimoto Chris H
CHIEF MEDICAL OFFICER		 Salg 7.58 11 901 1570 0 -0.01 link
14.06.2024 18.06.2024 Weber Steven
PRINCIPAL ACCOUNTING OFFICER		 Salg 7.58 3 752 495 0 0 link
28.03.2024 28.03.2024 BAKER BROS. ADVISORS LP
Director		 Kjøpe 9.62 937 690 97473 0 0.37 link
27.03.2024 28.03.2024 BAKER BROS. ADVISORS LP
Director		 Kjøpe 9.24 257 279 27844 0 0.11 link
26.03.2024 28.03.2024 BAKER BROS. ADVISORS LP
Director		 Kjøpe 8.26 2 230 200 270000 0 1.04 link
14.03.2024 15.03.2024 Decker Lisa Lynn
CHIEF BUSINESS OFFICER		 Salg 10.17 16 048 1578 0 -0.01 link
14.03.2024 15.03.2024 Keyt Bruce
CHIEF SCIENTIFIC OFFICER		 Salg 10.17 18 753 1844 0 -0.01 link
14.03.2024 15.03.2024 Schwarzer Fred
CEO AND PRESIDENT		 Salg 10.17 42 531 4182 0 -0.02 link
14.03.2024 15.03.2024 Tahir Misbah
CHIEF FINANCIAL OFFICER		 Salg 10.17 25 862 2543 0 -0.01 link
14.03.2024 15.03.2024 Takimoto Chris H
CHIEF MEDICAL OFFICER		 Salg 10.17 25 781 2535 0 -0.01 link
13.03.2024 15.03.2024 Decker Lisa Lynn
CHIEF BUSINESS OFFICER		 Salg 9.88 17 764 1798 0 -0.01 link
13.03.2024 15.03.2024 Keyt Bruce
CHIEF SCIENTIFIC OFFICER		 Salg 9.88 20 758 2101 0 -0.01 link
13.03.2024 15.03.2024 Schwarzer Fred
CEO AND PRESIDENT		 Salg 9.88 47 078 4765 0 -0.02 link
13.03.2024 15.03.2024 Tahir Misbah
CHIEF FINANCIAL OFFICER		 Salg 9.88 28 622 2897 0 -0.01 link
13.03.2024 15.03.2024 Takimoto Chris H
CHIEF MEDICAL OFFICER		 Salg 9.88 28 543 2889 0 -0.01 link
27.11.2023 29.11.2023 Keyt Bruce
Chief Scientific Officer		 Salg 5.06 4 721 933 0 0 link
27.11.2023 29.11.2023 Schwarzer Fred
CEO and President		 Salg 5.06 6 765 1337 0 -0.01 link
27.11.2023 29.11.2023 Tahir Misbah
Chief Financial Officer		 Salg 5.06 6 765 1337 0 -0.01 link
30.06.2023 03.07.2023 Topsoe Jakob Haldor
Director		 Kjøpe 9.25 32 375 3500 0 0.01 link
29.06.2023 03.07.2023 Topsoe Jakob Haldor
Director		 Kjøpe 9.1 31 850 3500 0 0.01 link
29.06.2023 03.07.2023 Redmile Group, LLC
Director		 Salg 9.42 757 585 80423 0 -0.31 link
29.06.2023 03.07.2023 Redmile Group, LLC
Director		 Kjøpe 9.42 757 585 80423 0 0.31 link
26.06.2023 28.06.2023 BEHRENS M KATHLEEN
Director		 Kjøpe 8 900 000 112500 0 0.43 link
23.05.2023 25.05.2023 Decker Lisa Lynn
Chief Business Officer		 Salg 12.31 15 498 1259 0 0 link
23.05.2023 25.05.2023 Gauthier George
Chief Commercial Officer		 Salg 12.31 15 498 1259 0 0 link
23.05.2023 25.05.2023 Keyt Bruce
Chief Scientific Officer		 Salg 12.31 12 088 982 0 0 link
23.05.2023 25.05.2023 Schwarzer Fred
CEO and President		 Salg 12.31 15 498 1259 0 0 link
23.05.2023 25.05.2023 Tahir Misbah
Chief Financial Officer		 Salg 12.31 15 498 1259 0 0 link
23.05.2023 25.05.2023 Takimoto Chris H
Chief Medical Officer		 Salg 12.31 15 498 1259 0 0 link
05.01.2023 09.01.2023 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 31 393 33756 0 0.13 link
04.10.2022 06.10.2022 Keyt Bruce
Chief Scientific Officer		 Salg 22.84 571 000 25000 0 -0.1 link
04.10.2022 06.10.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 23 250 25000 0 0.1 link
29.09.2022 03.10.2022 LOBERG MICHAEL D
Director		 Kjøpe 19.62 114 208 5821 0 0.02 link
22.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Salg 20.71 130 473 6300 0 -0.02 link
22.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 5 859 6300 0 0.02 link
19.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Salg 22.82 198 534 8700 0 -0.03 link
19.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 8 091 8700 0 0.03 link
18.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Salg 22.54 225 400 10000 0 -0.04 link
18.08.2022 22.08.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 9 300 10000 0 0.04 link
06.04.2022 08.04.2022 Keyt Bruce
Chief Scientific Officer		 Salg 25 62 500 2500 0 -0.01 link
06.04.2022 08.04.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 2 325 2500 0 0.01 link
01.04.2022 04.04.2022 BEHRENS M KATHLEEN
Director		 Kjøpe 23 1 399 990 60869 0 0.23 link
01.04.2022 04.04.2022 LOBERG MICHAEL D
Director		 Kjøpe 23 499 997 21739 0 0.08 link
30.03.2022 01.04.2022 Keyt Bruce
Chief Scientific Officer		 Salg 28.5 213 750 7500 0 -0.03 link
30.03.2022 01.04.2022 Keyt Bruce
Chief Scientific Officer		 Kjøpe 0.93 6 975 7500 0 0.03 link

Institusjoner Volum Dele, %
Baker Brothers Advisors, LLC 3691011 11.09
Price (T.Rowe) Associates Inc 3260022 9.79
Artal Group S.A. 3100422 9.31
Redmile Group, LLC 2971542 8.93
FMR, LLC 1698506 5.1
Goldman Sachs Group Inc 1040509 3.13
RA Capital Management, L.P. 937500 2.82
Vanguard Group Inc 897149 2.7
Blackrock Inc. 762470 2.29
Adage Capital Partners GP L.L.C. 400000 1.2

ETF Dele, % Lønnsomhet for året, % Utbytte, %
Range Cancer Therapeutics ETF 2.23113 47.24 0.11955
Virtus LifeSci Biotech Clinical Trials ETF 1.61159 63.04 0.33
iShares Micro-Cap ETF 0.06217 13.79 1.54048
iShares Russell 2000 Growth ETF 0.01665 38.04 0.6026
Vanguard Russell 2000 Growth ETF 0.01 17.39 0.60264
Vanguard Russell 2000 ETF 0.01 14.37 1.48801
Schwab U.S. Small-Cap ETF 0.00647 13.35 1.51433
ProShares UltraPro Russell2000 0.0053 89.82 1.47873
Avantis U.S Small Cap Equity ETF 0.00437 27.77 1.68271
ProShares Hedge Replication ETF 0.00153 5.92 1.47892
Schwab U.S. Broad Market ETF 0.0008 23.7 1.43354
iShares Russell 3000 ETF 0.00059 23.61 1.43482
Vanguard Russell 3000 ETF 0 31.87 1.43817



Veileder Stillingstittel Betaling Fødselsår
Mr. Paul C. Graffagnino Senior Vice President of Legal Affairs N/A
Ms. Suzette Tauber Chief Human Resources Officer N/A 1964 (61 år)
Dr. Angus M. Sinclair Ph.D. Senior Vice President of Immuno-Oncology N/A
Mr. Fred M. Schwarzer J.D. CEO, President & Director 977.66k 1953 (72 år)
Dr. Chris H. Takimoto FACP, M.D., Ph.D. Chief Medical Officer 684.95k 1959 (66 år)
Mr. Steven Weber Senior VP, Corporate Controller & Principal Accounting Officer N/A 1977 (48 år)
Mr. TS Harigopal Senior Vice President of Group Operations N/A
Dr. Lisa L. Decker Ph.D. Chief Business Officer 528.18k 1969 (56 år)
Dr. Bruce A. Keyt Ph.D. Chief Scientific Officer 1953 (72 år)
Mr. Misbah Tahir Chief Financial Officer 1975 (50 år)

Adresse: United States, Mountain View, CA , 325 East Middlefield Road - åpne i Google maps, åpne Yandex-kart
Nettsted: http://igmbio.com